Category: patents
-
STAT+: Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines
STAT+: Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines Moderna has agreed to pay Roivant up to $2.25 billion to settle claims that the mRNA vaccine developer infringed on Roivant’s patents in its Covid-19 shot. Roivant will receive $950 million and then another $1.3 billion if Moderna’s attempts…
-
STAT+: Trump administration is urged to use a federal law to authorize generic versions of GLP-1 drugs
STAT+: Trump administration is urged to use a federal law to authorize generic versions of GLP-1 drugs Public Citizen petitioned the Trump administration to use a federal law to authorize generic competitors for GLP-1 drugs for treating obesity and diabetes, arguing that prices are “unjustifiably high” for too many Americans. In arguing its case, the…
-
STAT+: Supreme Court agrees to review ‘skinny labeling’ and generic drug access
STAT+: Supreme Court agrees to review ‘skinny labeling’ and generic drug access The Supreme Court has agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines. Skinny labeling refers to moves by generic companies that seek regulatory approval…
-
STAT+: Trump administration launches investigation into Harvard’s federally funded research patents
STAT+: Trump administration launches investigation into Harvard’s federally funded research patents The U.S. Department of Commerce is opening an investigation into Harvard’s federally funded research programs amid allegations that it failed to follow the law, according to a senior administration official. In a letter sent to Harvard President Alan Garber on Friday, Commerce Secretary Howard…
-
STAT+: AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills
STAT+: AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills A patient advocacy group is suing the Trump administration for failing to disclose details of a recent settlement with Gilead Sciences over the patent rights to a pair of HIV prevention pills. The deal, which was reached last January, capped…
-
STAT+: ViiV expands licensing deal for its HIV drug in low-income countries
STAT+: ViiV expands licensing deal for its HIV drug in low-income countries Once again, ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, reflecting ongoing pressure to respond to criticism. Under the latest arrangement, the company is expanding a licensing agreement reached three years ago with…
-
STAT+: Merck gets lift from U.S. patent office in battle over injectable form of Keytruda
STAT+: Merck gets lift from U.S. patent office in battle over injectable form of Keytruda In a boost for Merck, a U.S. Patent and Trademark Office panel agreed to reconsider a patent granted to another company that could affect plans to broaden use of its franchise product, the Keytruda cancer treatment. The dispute with Halozyme…
-
Opinion: STAT readers on the animal wellness industry, drug price floors, and more
Opinion: STAT readers on the animal wellness industry, drug price floors, and more First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected…